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low-density malaria and infant HIV-1
viral load, the consequences of high-
density or clinical malaria need to be
explored. If clinical malaria in infants
increases HIV-1 viral load as it does
in adults (1,2), our study underscores
dual benefits of malaria treatment in
the context of HIV: 1) keeping malar-
ia in check, and 2) preventing an
increase in HIV viral load. Ethical
issues prevent prospective studies to
assess the impact of coinfection early
in life, but alternatives include using
animal models or stored specimens.
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African Tickbite
Fever in Travelers,
Swaziland 
To the Editor: African tickbite
fever (ATBF), which is caused by
Rickettsia africae, is well documented
in travelers to southern Africa (1–3)
and transmitted by ungulate ticks of
the genus Amblyomma. Positive sero-
logic results were reported in 9% of
patients (1) and 11% of travelers (4)
from southern Africa. We report an
outbreak of ATBF with an attack rate
of 100% among 12 Dutch travelers to
Swaziland.
The 12 travelers (9 male and 3
female) visited Mkhaya Game
Reserve in Swaziland in May 2003 for
several days. Upon retuning to the
Netherlands, they consulted our clinic
for assessment for fever, malaise, and
skin eruptions. Epidemiologic and
clinical data were obtained after the
patients provided informed consent.
All symptomatic patients were treated
before serum samples were collected. 
Acute-phase and convalescence-
phase serum samples were obtained
from 8 patients at 3 and 9 weeks,
respectively, after symptoms were
reported. Only convalescent-phase
serum samples were obtained from
the other 4 patients. Serologic assays
were conducted for screening and
confirmation in Rotterdam, the
Netherlands (Department of Virology,
Erasmus University Hospital) and
Marseille, France (Unité des
Rickettsies, Faculté de Médecine,
Université de la Mediterranée),
respectively. 
In Rotterdam, immunofluores-
cence assays for immunoglobulin G
(IgG) and IgM against R. conorii, R.
typhi, and R. rickettsii were per-
formed with multiwell slides on
which antigens were fixed (Panbio
Inc., Columbia, MD, USA). Serum
samples with fluorescent rickettsiae
at dilutions >1:32 were considered
positive.
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In Marseille, a microimmunofluo-
rescence assay for IgG and IgM
against R. africae, other members of
the spotted fever group, and R. typhi
of the typhus biogroup was used.
Western blotting for R. africae and R.
conorii was performed with reactive
serum samples and repeated after
cross-adsorption that removed only
antibodies to R. conorii (5). Serologic
evidence for infection with R. africae
was defined as 1) seroconversion; 2)
IgG titers >64, IgM titers >32, or
both, with IgG and IgM titers >2 dilu-
tions higher than any of the other test-
ed spotted fever group rickettsial anti-
gens; 3) a Western blot profile that
showed R. africae–specific antibod-
ies; and 4) cross-adsorption assays
that showed homologous antibodies
against R. africae (1).
All 12 travelers had a diagnosis of
ATBF. Epidemiologic, clinical, and
serologic results are shown in the
Table. Two patients had a history of a
tickbite. Lymphadenopathy in the
groin was the only clinical sign
observed in 2 other patients. For all 10
patients with symptoms, the symp-
toms abated within a few days after
treatment with doxycycline, 100 mg
orally twice a day (5 patients) for 7
days, or ciprofloxacin, 500 mg orally
twice a day (5 patients) for 7 days. No
relapses or complications were noted
1 year later. 
Assays in both locations showed
serologic reactivity against R. conorii
and R. rickettsiae. Specific antibodies
against R. africae were detected by
Western blot in 8 patients (Table). All
12 travelers were infected with R.
africae. In 3 other patients, immuno-
fluorescence assays demonstrated
seroconversion for specific antibod-
ies. One patient with no clinical
symptoms had low IgG (32) and IgM
(16) titers against rickettsiae by
immunofluorescence and IgG by
Western blot. 
Tick vectors of R. africae attack
humans throughout the year. The pro-
portion of patients having multiple
eschars, which indicate the aggressive
behavior of the tick, varies from 21%
(6) to 54% (2). The 100% attack rate
observed in this study emphasizes the
risk for ATBF in sub-Saharan travel-
ers. In our study group, only 2 persons
had multiple eschars, but serologic
analysis showed that all patients were
infected with R. africae. Most cases of
ATBF have a benign and self-limiting
course with fever, headache, myalgia,
and a skin rash. However, patients
who are not treated show prolonged
fever, reactive arthritis, and subacute
neuropathy (7). 
The long-term sequelae of ATBF
remain to be established. Early treat-
ment would not likely have prevented
these complications. Jensenius et al.
reported that travel from November
through April was a risk factor for
ATBF (1). The travelers in our study
visited Swaziland in May. We specu-
late that tick bites were likely caused
by larvae or nymphs, which are often
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unrecognized stages. Many affected
travelers may not seek medical atten-
tion or may have received a wrong
diagnosis. Therefore, surveillance
based only on reported cases is likely
to underestimate the true incidence of
travel-associated R. africae infection.
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Catheter-related
Bacteremia and
Multidrug-resistant
Acinetobacter 
lwoffii 
To the Editor: Acinetobacter
species are ubiquitous in the environ-
ment. In recent years, some species,
particularly A. baumannii, have
emerged as important nosocomial
pathogens because of their persistence
in the hospital environment and broad
antimicrobial drug resistance patterns
(1,2). They are often associated with
clinical illness including bacteremia,
pneumonia, meningitis, peritonitis,
endocarditis, and infections of the uri-
nary tract and skin (3). These condi-
tions are more frequently found in
immunocompromised patients, in
those admitted to intensive care units,
or in those who have intravenous
catheters, and those who are receiving
mechanical ventilation (4,5). 
The role of A. baumannii in noso-
comial infections has been document-
ed (2), but the clinical effect of other
Acinetobacter species has not been
investigated. A. lwoffii (formerly A.
calcoaceticus var. lwoffii) is a com-
mensal organism of human skin,
oropharynx, and perineum that shows
tropism for urinary tract mucosa (6).
Few cases of A. lwoffii bacteremia
have been reported (3,5–7). We report
a 4-year (2002–2005) retrospective
study of 10 patients with A. lwoffii
bacteremia admitted to a 600-bed
teaching hospital in central Italy. 
All 10 patients were immunocom-
promised; 8 had used an intravascular
catheter (peripheral or central) and 2
had used a urinary catheter. Blood
cultures of the patients were analyzed
with the BacT/ALERT 3D system
(bioMérieux, Marcy l’Etoile, France).
Isolates were identified as A. lwoffii
by using the Vitek 2 system and the
API 20NE system (both from
bioMérieux). 
Susceptibilities of 10 A. lwoffii iso-
lates to 18 antimicrobial drugs were
determined by the broth microdilution
method, according to Clinical and
Laboratory Standards Institute (CLSI,
formerly NCCLS) guidelines (8). The
drugs tested were amikacin, ampi-
cillin-sulbactam, aztreonam, cefe-
pime, cefotaxime, ceftazidime, ceftri-
axone, ciprofloxacin, gentamicin,
imipenem, levofloxacin, meropenem,
ofloxacin, piperacillin, piperacillin-
tazobactam, tetracycline, tobramycin,
and trimethoprim-sulfamethoxazole.
MIC was defined as the lowest drug
concentration that prevented visible
bacterial growth. Interpretative crite-
ria for each drug tested were as in
CLSI guidelines (8). A. lwoffii resist-
ant to >4 classes of drugs were
defined as multidrug-resistant (MDR)
isolates.  
A. lwoffii isolates were genotyped
by pulsed-field gel electrophoresis
(PFGE) to determine their epidemio-
logic relatedness. Chromosomal DNA
was digested with SmaI (9) and ana-
lyzed with a CHEF DR II apparatus
(Bio-Rad Laboratories, Hercules, CA,
USA). PFGE patterns were classified
as identical, similar (differed by 1–3
bands), or distinct (differed by >4
bands) (10). 
Among the 10 A. lwoffii isolates, 6
were susceptible to all drugs except
cephalosporins (cefepime, cefo-
taxime, ceftazidime, and ceftriaxone)
and aztreonam. The other 4 isolates
were MDR: 3 were susceptible only to
imipenem (MICs 1–4 µg/mL),
meropenem (MICs 1–2 µg/mL), and
amikacin (MICs 2–4 µg/mL). The
fourth MDR strain was susceptible to
imipenem (MIC 2 µg/mL), meropen-
em (MIC 2 µg/mL), amikacin (MIC 4
µg/mL), and ciprofloxacin (MIC 1
µg/mL). Seven antimicrobial drug
resistance profiles were detected
(Table).
Macrorestriction analysis of the A.
lwoffii isolates identified 8 distinct
PFGE types. Two MDR strains
(strains 2 and 3 in the Table), which
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